InVivo Therapeutics Holdings Corp. Stock Price and Value Analysis

Should you buy InVivo Therapeutics Holdings Corp. stock? (NasdaqCM:NVIV). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
None.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

NVIV Free Cash Flow Trend

Hmm, we can't give any reliable projection for InVivo Therapeutics Holdings Corp.'s growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for NVIV
Free Cash Flow trendline for InVivo Therapeutics Holdings Corp.

Inside the NVIV Numbers

NVIV Price
(InVivo Therapeutics Holdings Corp. stock price per share)
$2.02
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 64%

Is InVivo Therapeutics Holdings Corp. Stock on Sale?

Based on our analysis, we believe that you should not buy InVivo Therapeutics Holdings Corp. right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy NVIV Stock?

Does InVivo Therapeutics Holdings Corp. have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.